Fig. 4

IL-11 contributes to increased viability and chemoresistance in prostate cancer cells. A Western blot analyses displaying the dose-dependent expression of IL-11 and IL-11RA in prostate cancer cell lines PC3 and DU145 after treatment with various concentrations of docetaxel (DTX) for 48 h. B ELISA measuring IL-11 secretion in the prostate cancer cell lines PC3 and DU145 with or without DTX treatment(1 nM for 48 h). The error bars indicate the standard deviations of three experiments independently. C Line graphs representing the percentage of cell viability over a period of 6 days for prostate cancer cell lines PC3 and DU145, comparing the effects of IL-11 overexpression against the control. D Images of colony formation in prostate cancer cell lines PC3 and DU145, comparing the control and overexpression treated groups, alongside bar graphs quantifying the number of colonies formed, indicating a significant increase in colony formation upon IL-11 treatment. E Graphs plotting cell viability percentages against a range of DTX concentrations for prostate cancer cell lines PC3 and DU145, comparing control groups to those treated with IL-11 overexpression. F Graphs depicting the effect of recombinant human interleukin 11(RhIL-11) on the cell viability of prostate cancer cell lines PC3 and DU145 at various DTX concentrations compared to the DMSO control. G, H Microscopy images of prostate cancer cell lines PC3 (G) and DU145 (H) displaying live (green) and dead (red) cells in the control and IL-11-treated groups, as indicated by bright field and fluorescence staining (I, J). Bar graphs showing the percentage of dead cells in prostate cancer cell lines PC3 (I) and DU145 (J), comparing the control and IL-11-treated groups. *P < 0.05, **P < 0.01, ***P < 0.001